Zweig DiMenna Associates LLC Grows Position in Natera, Inc. $NTRA

Zweig DiMenna Associates LLC lifted its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 1.7% in the fourth quarter, HoldingsChannel.com reports. The firm owned 134,800 shares of the medical research company’s stock after acquiring an additional 2,300 shares during the quarter. Natera accounts for about 1.9% of Zweig DiMenna Associates LLC’s investment portfolio, making the stock its 14th largest holding. Zweig DiMenna Associates LLC’s holdings in Natera were worth $30,881,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. JPMorgan Chase & Co. grew its holdings in shares of Natera by 9.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company’s stock worth $1,871,914,000 after purchasing an additional 1,003,129 shares during the period. State Street Corp grew its holdings in shares of Natera by 2.2% during the 3rd quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock worth $545,624,000 after purchasing an additional 72,087 shares during the period. Franklin Resources Inc. grew its holdings in shares of Natera by 37.5% during the 3rd quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock worth $428,987,000 after purchasing an additional 727,366 shares during the period. Geode Capital Management LLC grew its holdings in shares of Natera by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 2,608,644 shares of the medical research company’s stock worth $596,078,000 after purchasing an additional 11,689 shares during the period. Finally, Fred Alger Management LLC grew its holdings in shares of Natera by 1.7% during the 3rd quarter. Fred Alger Management LLC now owns 2,451,779 shares of the medical research company’s stock worth $394,663,000 after purchasing an additional 41,303 shares during the period. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Price Performance

Shares of Natera stock opened at $223.37 on Friday. The business has a 50-day moving average of $202.37 and a 200 day moving average of $215.69. Natera, Inc. has a 12 month low of $131.81 and a 12 month high of $256.36. The stock has a market capitalization of $31.99 billion, a price-to-earnings ratio of -137.04 and a beta of 1.57.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, February 26th. The medical research company reported $0.35 EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.81. Natera had a negative return on equity of 14.74% and a negative net margin of 9.05%.The company had revenue of $665.50 million during the quarter, compared to analysts’ expectations of $600.68 million. During the same period last year, the business posted ($0.41) EPS. Equities research analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on NTRA. JPMorgan Chase & Co. increased their price target on Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Piper Sandler reiterated an “overweight” rating and set a $249.00 price target on shares of Natera in a report on Tuesday, May 12th. Morgan Stanley lowered their price target on Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a report on Tuesday, March 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a report on Tuesday, April 21st. Finally, Evercore reiterated an “outperform” rating and set a $270.00 price target on shares of Natera in a report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $256.60.

Key Stories Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera announced a new collaboration with Diakonos Oncology to use Signatera in a Phase I/II study for refractory melanoma, expanding a key cancer-testing product into another clinical use case and reinforcing its oncology growth story. Article Title
• Positive Sentiment: Canaccord raised its price target on Natera to $250 from $200, signaling stronger confidence in the company’s outlook and helping fuel bullish sentiment. Article Title
• Positive Sentiment: Natera is also drawing attention from investors after commentary calling it a favorite stock idea for the rest of 2026, which adds to the momentum around the name. Article Title

Insider Transactions at Natera

In other Natera news, CFO Michael Burkes Brophy sold 3,070 shares of the stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $193.74, for a total value of $594,781.80. Following the sale, the chief financial officer owned 58,291 shares of the company’s stock, valued at $11,293,298.34. This trade represents a 5.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Leonard Chapman sold 5,838 shares of the stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $204.14, for a total value of $1,191,769.32. Following the completion of the sale, the chief executive officer directly owned 150,769 shares in the company, valued at $30,777,983.66. This represents a 3.73% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 41,356 shares of company stock valued at $8,374,584. Insiders own 5.63% of the company’s stock.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.